A new analysis of 11 clinical trials looked at whether drugs called tyrosine kinase inhibitors (TKIs) can help dogs with lymphoma, a common cancer. The analysis included 101 dogs. Overall, about 42% of the dogs had a positive response to treatment, meaning their tumors shrank or disappeared. The response rate was higher for T-cell lymphoma (63%) than for B-cell lymphoma (27%).
TKIs are a type of targeted therapy that blocks signals cancer cells use to grow. They are already used in human medicine for certain cancers. This analysis suggests they may also be useful for dogs, and because dog lymphomas are similar to some human lymphomas, the findings could help guide research in people.
The study did not report on side effects or how well the dogs tolerated the treatment. Also, the analysis did not compare TKIs to other treatments, so it is not clear if they are better or worse than standard options.
The main limitation is that this is a meta-analysis of existing trials, and the authors say further studies are needed to confirm how well these drugs work and how safe they are. Also, the best way to combine TKIs with other treatments or personalize them for individual dogs has not been explored yet.
For dog owners, this is encouraging news, but it does not mean TKIs are ready for everyday use. Talk to your veterinarian about the best treatment plan for your pet.
